Kristin Spinelli
Family · Toledo, OHNPI 1134435027
Payments from drug & device makers
Across 447 payments — averaging $17.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$966
- AstraZeneca$879
- GSK$607
- Pfizer$565
- Boehringer Ingelheim$446
- plus $3K from 31 others
What the payments were for
- Food & beverage$7,946100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 83 | $1,030 |
| AbbVie | 44 | $966 |
| AstraZeneca(2 entities) | 25 | $879 |
| GSK | 38 | $607 |
| Pfizer | 37 | $565 |
| Boehringer Ingelheim | 27 | $446 |
| Lilly USA, LLC | 35 | $405 |
| Bayer | 17 | $272 |
| Exact Sciences | 14 | $270 |
| Johnson & Johnson | 14 | $243 |
| Amgen(2 entities) | 15 | $236 |
| Amarin Pharma, Inc. | 12 | $194 |
| Lundbeck LLC | 9 | $185 |
| Corcept Therapeutics | 5 | $183 |
| Novartis | 9 | $178 |
| Abbott | 5 | $176 |
| Axsome Therapeutics, Inc. | 6 | $158 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $130 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $76 |
| Janssen Scientific Affairs, LLC | 1 | $75 |
| Eisai Inc. | 5 | $68 |
| Dexcom, Inc. | 3 | $66 |
| E.r. Squibb & Sons, L.L.C. | 4 | $65 |
| Kowa Pharmaceuticals America, Inc. | 4 | $61 |
| Merck | 4 | $58 |
| Esperion Therapeutics, Inc. | 3 | $45 |
| Seqirus USA Inc | 2 | $42 |
| Otsuka America Pharmaceutical, Inc. | 2 | $40 |
| Sumitomo Pharma America, Inc. | 2 | $39 |
| Phathom Pharmaceuticals, Inc. | 2 | $36 |
| Astellas Pharma US Inc | 2 | $30 |
| Biohaven Pharmaceuticals, Inc. | 2 | $27 |
| Almatica Pharma LLC | 2 | $26 |
| Phadia US Inc. | 1 | $20 |
| Gilead | 1 | $18 |
| Radius Health, Inc. | 1 | $18 |
| Shield Therapeutics Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,946 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 121 | $121,499 |
| OzempicSemaglutide | 67 | $92,608 |
| EliquisApixaban | 41 | $51,400 |
| XareltoRivaroxaban | 53 | $48,329 |
| TrulicityDulaglutide | 23 | $35,837 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $29,517 |
| MounjaroTirzepatide | 19 | $27,614 |
| JanuviaSitagliptin Phosphate | 17 | $19,376 |
| Repatha SyringeEvolocumab | 25 | $17,805 |
| FarxigaDapagliflozin Propanediol | 12 | $16,976 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 31 | $12,152 |
| Atorvastatin Calcium | 482 | $5,725 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 14 | $4,525 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,177 |
| Levothyroxine Sodium | 377 | $3,521 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $446 | $121,499121 claims |
| Novo NordiskOzempic | $1,030 | $92,60867 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $405 | $63,45042 claims |
| PfizerEliquis, Paxlovid | $565 | $54,22554 claims |
| Johnson & JohnsonXarelto | $243 | $48,32953 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $607 | $33,69538 claims |
| AstraZenecaFarxiga, Lokelma | $879 | $20,00723 claims |
| MerckJanuvia | $58 | $19,37617 claims |
| Almatica Pharma LLCSertraline Hcl | $26 | $1,556199 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.
Other family in Toledo
- Kirt MunsonToledo$108K
- Sheri LukeToledo$31K
- Kyle PatchenToledo$25K
- Alexander NorwoodToledo$17K
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.